Novartis has discovered a new Xolair® indication for the treatment of severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for adults.
Xolair® (omalizumab), is the first discovered treatment option for CRSwNP which specifically targets and blocks the growth of Immunoglobulin E (IgE), which is supposed to be a key driver in the inflammatory pathway of the disease.
Xolair® (omalizumab) discovered has the ability to block immunoglobulin E. Once approved it can provide a new treatment option for patients for whom intranasal corticosteroids do not generate adequate disease control. Moreover, it also shows significant symptoms in patients thereby improving the patient’s quality of life.
European Commission (EC) has approved Xolair® (omalizumab) as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps.
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) occurs in adults by affecting inflammation of the nose and paranasal sinuses which normally blocks the airflow in the nose with the existence of nasal polyps.
Patients with severe chronic rhinosinusitis with nasal polyps can be often seen suffering with symptoms such as nasal congestion, facial pain, loss of sense of smell and taste, difficulty in breathing and sleep problems affecting their quality of life.
